$150K - $200K(Ladders Estimates)
This position is accountable for developing and driving the early oncology development strategy of assets in the EODCR group in ORD, a division of WRD, in alignment with the overall EODCR and Pfizer portfolio strategy. The Early Development Asset Team Leader (ATL) leads the Asset Team (AT) and is accountable for the seamless execution of all project deliverables from candidate selection and IND enabling deliverables leading to First in Subject/Patient and up to a point, at which time the asset may transition to the appropriate late phase development organization. The ATL will be responsible for approval of program and/or project plans, endorsing and integrating line function strategies, and is the single point of accountability for the seamless execution of program deliverables and decisions for each asset.
The Early Development ATL applies scientific knowledge, clinical and drug development experience to ensure research and development strategy of the AT can address unmet need and commercial strategies. The ATL will also be responsible for interfacing with external scientists as well as with internal Pfizer experts to assure the swift identification of new early development opportunities to continuously optimize and refine the development strategy. Together with the Clinical Lead, the ATL will determine the clinical development plan that supports key deliverables and timely go-no go decisions to the next stage of development. Leadership provided by the ATL will ensure the application of robust, innovative and strategic approaches to fully characterize the early safety and efficacy profile of the experimental therapy, to optimally inform late stage clinical development strategies and to increase the probability of successful development of the asset. The ATL will be a decisive leader who can apply cost effective, time efficient and high quality approaches to drug development. The ATL will manage and be accountable for strategies implemented by the AT (comprising cross-functional leads: clinical, regulatory, pharmaceutical sciences, manufacturing, etc) for ORD assets as a leader of a global cross-functional team and will assure the smooth passage of experimental medicines from ORD through First-in-Subject/Patient (or from in-licensing) to the late stage development. In addition, the ATL will be a coach/mentor to AT members.
Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care provider's name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.
EEO & Employment Eligibility
Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.
Valid Through: 2019-10-3